Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04260932
Recruitment Status : Recruiting
First Posted : February 7, 2020
Last Update Posted : March 23, 2021
China Immunotech (Beijing) Biotechnology Co., Ltd.
Information provided by (Responsible Party):
Hebei Yanda Ludaopei Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 10, 2021
Estimated Study Completion Date : November 10, 2021